It's up to SH to hold the CEO to task,, Myself and few other...

It's up to SH to hold the CEO to task,, Myself and few other Holders primary interest is SNT 6302 Topical Anti Scaring Cream. Noted in the presentation is the SNT 6302 scaring clinical development to be announced Q4 2024.

Topical pan-LOX inhibitors in
Skin Scarring
• Clinical PoC: significant
reduction of collagen and good
safety in 3-month placebocontrolled Phase 1c study in
patients with established scars

• Lead and back up compounds
to support studies in multiple
scar types (prevention of scar
formation and modification of
existing scars) in topical and
oral dosage form

• Strong preclinical evidence in
models of skin fibrosis and
scarring; Nature publication

• Patent priority date of 2019
provides extended IP coverage

I'm not 100% sold on the CEO , great speaker and presentation skills but I do 100% believe in Dr Fiona Wood and her previous statements surrounding the Phase I that was hugely successful..

Trading patterns are erratic at best with SNT ,, last week we were pushing 3m 5m 4m volume days with corresponding increases in Value ,,NZT